A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Noroviruses (NoV) are the leading cause of epidemic acute gastroenteritis in humans worldwide and a safe and effective vaccine is needed. Here, a phase I, double-blind, placebo-controlled clinical trial was performed in 60 healthy adults, 18 to 40 years old. Safety (primary objective) and immunogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroux-Roels, Isabel, Maes, Cathy, Joye, Jasper, Jacobs, Bart, Jarczowski, Franziska, Diessner, André, Janssens, Yorick, Waerlop, Gwenn, Tamminen, Kirsi, Heinimäki, Suvi, Blazevic, Vesna, Leroux-Roels, Geert, Klimyuk, Victor, Adachi, Hiroshi, Hiruta, Kazuyuki, Thieme, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585308/
https://www.ncbi.nlm.nih.gov/pubmed/36275772
http://dx.doi.org/10.3389/fimmu.2022.1021500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585308/
https://www.ncbi.nlm.nih.gov/pubmed/36275772
http://dx.doi.org/10.3389/fimmu.2022.1021500

Ejemplares similares